N/A
N=183
Myopia Control With the Multi-segment Lens
Myopia
Bottom Line
View on ClinicalTrials.gov: NCT02206217 ↗Enrolled (actual)
183
Serious AEs
0.0%
Results posted
Jul 2019
Primary outcome: Primary: Cycloplegic Refraction Change in SER — -0.93; -0.38 Diopters (D)
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Multiple-Segment spectacle lens (Device)
- Age
- Pediatric · 8+ yrs
- Sex
- All
- Sponsor
- The Hong Kong Polytechnic University
- Primary completion
- Jul 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cycloplegic Refraction Change in SER |
-0.93; -0.38 | — |
| SECONDARY Axial Length |
0.53; 0.21 | — |
Summary
The purpose of this study is to determine if the Multiple-Segment (MS) spectacle lens can slow myopia progression in Hong Kong schoolchildren.
MS lens is also called Defocus Incorporated Multiple Segments (DIMS) spectacle lens
Eligibility Criteria
Inclusion Criteria
- Age at enrolment: 8-13 year
- Spherical equivalent refractions (SER): -1.00 to -5.00 Dioptres (D)
- Astigmatism and anisometropia of 1.50 D or less
- Spectacle corrected monocular logMAR visual acuity: 0 or better
- Parents' understanding and acceptance of random allocation of grouping
Exclusion Criteria
- any ocular and systemic abnormalities might affect visual functions or refractive development
- prior treatment of myopic control, e.g. drugs, orthokeratology, progressive addition lenses, bifocal lenses, drugs (e.g. atropine), etc.
Data sourced from ClinicalTrials.gov (NCT02206217). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.